Educate
Collaborate
Transform
Our Mission >>
UPCOMING EVENTS
79th Annual Conference of the Association of Physicians of India
New Delhi, India
February 22-25
21st International Congress of Endocrinology in conjunction with Emirates Diabetes and Endocrine Congress
Dubai, United Arab Emirates
March 1-3
17th International Conference on Advanced Technologies & Treatments for Diabetes
Florence, Italy
6-9 March 2024
22nd European Congress of Internal Medicine
Istanbul, Turkey
March 7-9
Societe Francophone du Diabete
Toulouse, France
March 19-22
American College of Cardiology Annual Scientific Session & Expo
Atlanta, Georgia
April 6-8
Now on Demand
“What’s New in MASLD: A Diagnosis and Management Update for the Busy Clinician” is a one-hour program that addresses the epidemic of Metabolic Dysfunction Associated Liver Disease (MASLD, formerly known as NAFLD). It provides an increased understanding of why MASLD is affecting a significant percentage of people with diabetes, clear direction on early diagnosis that will lead to better patient management, and new treatment options, as well as guidelines that have been proven to be effective. The renowned faculty provide valuable information about the extent to which diabetes increases the risk of MASLD and what the clinician needs to look for.
Click here to view the program and be sure to complete the program evaluation. Your
comments are very important to us as we develop future educational initiatives.
This program is sponsored by the Worldwide Initiative for Diabetes Education and supported by
an educational grant from Novo Nordisk A/S.
“Harnessing the Power of AI to Help Eliminate Preventable Blindness” was presented live in partnership
with the International Diabetes Foundation (IDF) Virtual Congress 2023 last December. It is now available as an on-demand program for
continued viewership. This one-hour program, chaired by Prof. Andrew J.M. Boulton from the University
of Manchester in Manchester, England, discusses the evolution of eye screening technology, the new
science of artificial intelligence (AI) technology, and data regarding AI screening and how it can impact
clinical practice. Given that diabetic retinopathy affects approximately 30 percent of persons with
diabetes and is one of the most prevalent eye afflictions in existence today, the use of AI technology in
eye screening is a significant advancement.
Joining Prof. Boulton in this program are:
- David Kerr, MB ChB, DM, FRCPE, FRCP
Sutter Center for Health Systems Research
Sacramento, CA, USA - Jennifer Lim, MD, FARVO
University of Illinois at Chicago
Chicago, IL, USA - Steven Yeh, MD, FASRS
University of Nebraska Medical Center
Omaha, NE, USA
This program is sponsored by the Worldwide Initiative for Diabetes Education and supported by an unrestricted educational grant from Eyenuk, Inc.